Valerio Therapeutics
Dexrazoxane Hydrochloride(Valerio Therapeutics)은 Acute Myeloid Leukemia 표적 ADC로, Cardiac Toxicity; Inflammatory Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: target key signaling pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 78.6% (ClinicalTrials.gov NCT03786783). 차별점: novel disease-modifying strategy in a condition where current treatments remain largely symptomatic.
Acute Myeloid Leukemia
Cardiac Toxicity; Inflammatory Breast Cancer
Recruiting
CAR-T cells - also carry cardiotoxic potential, warranting t
linker, and para hydroxyl benzene ring were advantageous pharmacophores for above two
novel disease-modifying strategy in a condition where current treatments remain largely symptomatic
target key signaling pathway
immune-mediated myocarditis
apoptosis; however, effective cardioprotective strategies remain inadequate
biomarkers
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Valerio Therapeutics
Dexrazoxane Hydrochloride(Valerio Therapeutics)은 Acute Myeloid Leukemia 표적 ADC로, Cardiac Toxicity; Inflammatory Breast Cancer 영역에서 개발·상용화 중입니다. 작용기전: target key signaling pathway. Phase 3 후기 임상 단계입니다. 대표 임상 효능: ORR 78.6% (ClinicalTrials.gov NCT03786783). 차별점: novel disease-modifying strategy in a condition where current treatments remain largely symptomatic.
Acute Myeloid Leukemia
Cardiac Toxicity; Inflammatory Breast Cancer
Recruiting
CAR-T cells - also carry cardiotoxic potential, warranting t
linker, and para hydroxyl benzene ring were advantageous pharmacophores for above two
novel disease-modifying strategy in a condition where current treatments remain largely symptomatic
target key signaling pathway
immune-mediated myocarditis
apoptosis; however, effective cardioprotective strategies remain inadequate
biomarkers
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.